Using RNA Analytics and Predictive AI
AMPEL Genomic Platform (AGP®) supports
genomic blood and biopsy tests for patients:
Evaluate disease status
Identify cells, functions and pathways
Predict flares and drug targets
RNA-Based Precision Medicine
One Platform, Many Solutions
Lifetime Disease Management
Products AMPEL
is Launching:
– LuGENE, Exp Q3 2023
– DermaGENE, Exp Q3 2024
– WellGENE, Exp Q3 2025
Key Stats
95%
coverage of all known genes and is disease agnostic
20,000+
autoimmune and normal patient gene expression profiles with rich clinical information – world’s largest for Lupus
35+
technology patents filed & pending with the freedom to operate
20+
pharma customers validate the technology
5+
additional autoimmunity products in development
Featured News
AMPEL BioSolutions’ Precision Medicine Breakthrough Predicts Drug Options with RNA Analytics & Machine Learning
Virginia Workforce Award to AMPEL BioSolutions
AMPEL on Bloomberg Markets
Lupus, coronary artery disease share genetic risk factors; data may lead to early testing
Local company unveils blood test to find treatments for chronic pain
Local company unveils blood test to find treatments for chronic pain
AMPEL BioSolutions Enters MDx Market With Lupus, Dermatology Gene Expression Assays
Innovator-of-Year to AMPEL
About the Founders
AMPEL’s co-founders, Amrie Grammer and Peter Lipsky, are internationally recognized scientists and successful entrepreneurs. Their success has been a combination of world-class science with business acumen. In 2023, AMPEL was recognized as Virginia’s Innovator-of-the-Year by CBIC. Last year, the Coalition of 21st Century Precision Medicine elected AMPEL to membership. Earlier this year, AMPEL was ranked by Nature in the top Precision Medicine Companies with respect to the impact of published science (Foundation Medicine, Illumina, Tempus, ThermoFischer, AMPEL BioSolutions, Guardant Health, AdaptiveTechnologies) and received a Virginia Catalyst Award